Oral nystatin as antifungal prophylaxis in critically ill patients: An old SDD tool to be renewed?

Intensive Care Medicine

Volumn 31, Issue 11, 2005, Pages 1466-1468

  Eggimann, Philippe ^a   Wolff, Michel ^b   Garbino, Jorge ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b BICHAT HOSPITAL   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; NYSTATIN; PYRROLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CLINICAL RESEARCH; CRITICAL ILLNESS; DRUG EFFICACY; EDITORIAL; FUNGAL STRAIN; HUMAN; IMMUNE DEFICIENCY; MICROBIAL COLONIZATION; MYCOSIS; NONHUMAN; RISK FACTOR;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE; NYSTATIN; RANDOMIZED CONTROLLED TRIALS;

EID: 27744536519     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2806-y     Document Type: Editorial

References (21)

1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645
2. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sablen C, Kartsonis N, Perfect J for the Caspofungin Invasive Candidiasis Study Group (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
3. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 51:95-101
4. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically-ill non-immunosuppressed patients. Lancet Infect Dis 3:685-702
5. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1989) Risk factors for hospital-acquired candidemia. Arch Intern Med 149:2349-2353
6. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance of Candida isolated from peritoneum in surgical patients Lancet II: 1437-440
7. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177-186
8. Bow EJ, Laverdiere M, Lussier N, Totstein C, Cheang MS, Ioannou S (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94:3230-3246
9. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis Clin Infect Dis 38:161-189
10. Anaissie EJ, Rex JH, Uzun O, Vartivarian S (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104:238-245
11. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071-1079
12. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA,Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
13. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, SENTRY participant groups (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40:852-856
14. Garbino J, Lew PD, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients. A randomized, double-blind, placebo-controlled trial in SDD-treated patients. Intensive Care Med 28:1708-1717
15. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31:752-757
16. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Milloin L, Boillot A (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically-ill surgical patients. Crit Care Med 32:2443-2449
17. Eggimann P, Francioli P, Bille J, Schneider R, WU MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066-1072
18. Cruciani M, de Lalla F, Mengoli C (2005) Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med (10.1007/s00134-005-2794-y)
19. Normand S, François B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, Gastinne H, Vignon P (2005) Oral nystatin prophylaxis of Candida spp. Colonization in ventilated critically-ill patients. Intensive Care Med (DOI: 10.1007/s00134-005-2807-x)
20. Gotzsche PC, Johansen HK (2002). Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev
21. Silvestri L, van Saene HK, Milanese M, Gregori D (2005) Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials. Intensive Care Med 31:898-910